| "To evaluate the treatment of bacterial vaginosis with metronidazole to determine if there is a therapeutic regimen that is superior to all others with regard to cure and recurrence rates." | ( Green, M; Lugo-Miro, VI; Mazur, L, 1992) |
| "These data suggest that patients with bacterial vaginosis should be treated in conjunction with first-trimester abortion because treatment with metronidazole reduces the postoperative infection rate more than three times." | ( Forsum, U; Larsson, PG; Påhlson, C; Platz-Christensen, JJ; Thejls, H, 1992) |
| "Treatment of bacterial vaginosis with clindamycin vaginal cream did not reduce preterm delivery or low birth weight." | ( Hillier, SL; Idajadi, A; Joesoef, MR; Linnan, M; Norojono, W; Sumampouw, H; Utomo, B; Wiknjosastro, G, 1995) |
| "Treatment options for bacterial vaginosis are numerous." | ( Ferris, DG; Hendrich, J; Litaker, MS; Mathis, D; Woodward, L, 1995) |
| "We reviewed data on the treatment of bacterial vaginosis published from 1989 through 1992 (articles published after the 1989 publication of the Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines)." | ( Joesoef, MR; Schmid, GP, 1995) |
| "Studies addressing the complications of bacterial vaginosis in pregnancy, the risk of treatment in pregnancy, and the method of transmission of the disease also were reviewed." | ( Schlicht, JR, 1994) |
| "To characterize the natural history of bacterial vaginosis in pregnancy and to assess the efficacy of short courses of oral metronidazole therapy for long-term suppression of bacterial vaginosis flora." | ( Jolley, PT; McDonald, HM; McDonald, PJ; O'Loughlin, JA; Vigneswaran, R, 1994) |
| "Treatment of bacterial vaginosis with metronidazole was effective in reducing preterm births in patients with a history of prematurity in the preceding pregnancy." | ( Albritton, J; Morales, WJ; Schorr, S, 1994) |
| "Within this study, women with bacterial vaginosis (16 to 27 week' gestation) were treated with 2% clinadmycin vaginal cream or placebo." | ( French, JI; Jones, W; McGregor, JA; McKinney, PJ; Milligan, K; Parker, R; Patterson, E, 1994) |
| "Among the 480 women with bacterial vaginosis treatment had no effect on spontaneous preterm birth (11/242 [4." | ( Bof, A; Harvey, JA; Jolley, PT; McDonald, HM; McDonald, PJ; O'Loughlin, JA; Vigneswaran, R, 1997) |
| "Of the 514 evaluable women enrolled, bacterial vaginosis was cured at the first return visit among evaluable patients in 153 of 199 (77%) of those who received the once-daily and in 157 of 196 (80%) of those who received the twice-daily administration." | ( Blackwelder, T; Fenner, DE; Ismail, M; Lappin, M; Livengood, CH; Long, BJ; Martens, MG; Nelson, AL; Sagov, S; Sheehan, KL; Soper, DE; Sweet, RL; Thorp, JM, 1999) |
| "Successful treatment outcomes for bacterial vaginosis occurred in 27 and 28 patients for Metrogel Vaginal and metronidazole, respectively, out of the original 30 patients in each study group." | ( Greenberg, R; McComish, JF; Ransom, SB; Tolford, DA, 1999) |
| "The most cost-effective treatment for bacterial vaginosis was generic metronidazole." | ( Greenberg, R; McComish, JF; Ransom, SB; Tolford, DA, 1999) |
| "In clinical trials, the treatment of bacterial vaginosis in pregnant women who previously had a preterm delivery reduced the risk of recurrence." | ( Carey, JC; Ernest, JM; Fischer, ML; Hauth, JC; Heine, RP; Hillier, SL; Klebanoff, MA; Leveno, KJ; Nugent, RP; Thom, EA; Varner, M; Wapner, R, 2000) |
| "The treatment of asymptomatic bacterial vaginosis in pregnant women does not reduce the occurrence of preterm delivery or other adverse perinatal outcomes." | ( Carey, JC; Ernest, JM; Fischer, ML; Hauth, JC; Heine, RP; Hillier, SL; Klebanoff, MA; Leveno, KJ; Nugent, RP; Thom, EA; Varner, M; Wapner, R, 2000) |
| "To determine whether treatment of bacterial vaginosis (BV) with vaginal clindamycin affects pregnancy outcome." | ( Jouppila, P; Kekki, M; Koskela, M; Kurki, T; Kurkinen-Räty, M; Paavonen, J; Vuopala, S, 2000) |
| "Half of all women with bacterial vaginosis are free of symptoms, and treatment of these women is controversial." | ( Schwebke, JR, 2000) |
| "To determine whether treatment of bacterial vaginosis (BV) in early pregnancy decreases the risk of preterm delivery and peripartum infectious morbidity." | ( Cacciatore, B; Kekki, M; Kurki, T; Kurkinen-Räty, M; Paavonen, J; Pelkonen, J, 2001) |
| "Eighty-nine women with either bacterial vaginosis, Trichomonas vaginalis, or both, who also had a positive fetal fibronectin test result were randomized to two courses of metronidazole treatment as part of a Maternal-Fetal Medicine Network Units study of the National Institute of Child Health and Human Development." | ( Carey, JC; Goldenberg, RL; Klebanoff, M; Macpherson, C, 2001) |
| "To assess the efficacy of treatment of bacterial vaginosis (BV) using metronidazole to reduce preterm labour in primigravidae and multigravidae with previous midtrimester abortion or preterm labour." | ( Grové, D; Odendaal, HJ; Popov, I; Schoeman, J; Smith, M, 2002) |
| "Treatment of asymptomatic bacterial vaginosis or T." | ( Carey, JC; Klebanoff, MA, 2001) |
| "Treatment of bacterial vaginosis with a single application of 100mg metronidazole in a bioadhesive vaginal tablet was found to be a valid alternative." | ( Casteels, M; Remon, JP; Temmerman, M; Voorspoels, J, 2002) |
| "The diagnosis and management of bacterial vaginosis are discussed, including the role of the nurse and midwife in testing and treatment." | ( Young, F, 2002) |
| "To evaluate the effect of treatment of bacterial vaginosis with the product Arilin rapid containing vaginal Metronidazole in high doses and a following vaginal application of lactic acid in a part of the patients." | ( Andreeva, P; Kovachev, S; Nacheva, A; Slavchev, B; Vacheva, R, 2002) |
| "For the period May 2001-August 2001, bacterial vaginosis was established in 45 patients of the Specialized hospital for active treatment in obstetrics and gynecology "Maichin Dom", Sofia and the Military medical academy-Sofia, gynecology ward." | ( Andreeva, P; Kovachev, S; Nacheva, A; Slavchev, B; Vacheva, R, 2002) |
| "Treating symptomatic bacterial vaginosis (BV) early in pregnancy may decrease preterm birth (PTB)." | ( Callahan, DB; Gunn, RA; Weinberg, M, 2003) |
| "Pregnant women with bacterial vaginosis diagnosed both by Gram stain and clinical criteria were randomized to receive oral (n=52) or vaginal (n=50) metronidazole therapy." | ( Hillier, SL; Landers, DV; Meyn, L; Yudin, MH, 2003) |
| "Treatment of bacterial vaginosis with clindamycin is associated with marked evidence of antimicrobial resistance among vaginal anaerobic bacteria." | ( Austin, MN; Beigi, RH; Hillier, SL; Krohn, MA; Meyn, LA, 2004) |
| "She was treated for recurrent bacterial vaginosis with multiple courses of metronidazole gel 0." | ( Baylson, FA; Nyirjesy, P; Weitz, MV, 2004) |
| "Treatment options for recurrent bacterial vaginosis are currently limited." | ( Baylson, FA; Nyirjesy, P; Weitz, MV, 2004) |
| "Women with bacterial vaginosis as defined by Amsel's criteria were treated with clindamycin ovules." | ( Carlsson, B; Eriksson, K; Forsum, U; Larsson, PG, 2005) |
| "Treatment of vaginitis and bacterial vaginosis with anyone of both formulations has the same clinical and microbiological effectiveness, and is well tolerated by the patient." | ( Garibay, M; Godínez, V; Mirabent, F; Pérez Calderón, A, 2005) |
| "We wished to determine recurrences of bacterial vaginosis (BV) after treatment over the course of 12 months and to establish factors associated with recurrence." | ( Bradshaw, CS; Fairley, CK; Garland, SM; Hocking, J; Horvath, LB; Kuzevska, I; Morris, MB; Morton, AN; Moss, LM, 2006) |
| "To screen for bacterial vaginosis (BV) and to investigate the effect of treatment with vaginal clindamycin in order to observe the effect on late miscarriage and delivery prior to 37 completed weeks (primary outcome)." | ( Carlsson, B; Fåhraeus, L; Forsum, U; Jakobsson, T; Larsson, PG, 2006) |
| "PCR was used to survey bacterial vaginosis flora before and after metronidazole treatment." | ( Ferris, MJ; Martin, DH; Norori, J; Zozaya-Hinchliffe, M, 2007) |
| "None developed bacterial vaginosis (BV) from normal vaginal flora, 69% of women had normal flora at baseline increasing to 91% following hormonal treatment." | ( Balen, AH; Lee, RA; Rutherford, AJ; Wilson, JD, 2007) |
| "Women (n = 100) with bacterial vaginosis diagnosed by Amsel criteria were after informed consent offered vaginal clindamycin therapy followed by vaginal gelatine capsules containing either 109 freeze-dried lactobacilli or identical placebo capsules for 10 days during 3 menstrual cycles in a double-blind, randomized, placebo-controlled trial." | ( Larsen, S; Larsson, PG; Ryttig, KR; Stray-Pedersen, B, 2008) |
| "To define risks for bacterial vaginosis persistence, including pretreatment detection of specific vaginal bacteria, among women reporting sex with women." | ( Fiedler, TL; Fredricks, DN; Marrazzo, JM; Ringwood, K; Thomas, KK, 2008) |
| "Eighty-four patients with bacterial vaginosis diagnosed according to Amsel's criteria were randomized to receive either oral metronidazole 500 mg twice a day for seven days, or one vaginal tablet containing freeze-dried Lactobacillus rhamnosus once a week at bedtime for two months starting one week after the last antibiotic administration." | ( Bertini, M; Calzolari, E; Marcone, V, 2008) |
| "vulvovaginitis-bacterial vaginosis and to check their prevention by drug treatments in the usual clinical practice." | ( Acs, N; Bánhidy, F; Czeizel, AE; Puho, EH, 2009) |
| "Twenty women with bacterial vaginosis were treated with 400 mg moxifloxacin for 5 days." | ( Dörffel, Y; Loening-Baucke, V; Mendling, W; Schilling, J; Swidsinski, A, 2011) |
| "To present the prevalence of bacterial vaginosis in threatened preterm, preterm, and term labor and results after treatment." | ( Chawanpaiboon, S; Pimol, K, 2010) |
| "Since bacterial vaginosis (BV) is characterized by a lack of, or very few, lactobacilli and high numbers of small, mostly anaerobic bacteria, an obvious treatment modality would be eradication of the BV-associated bacterial flora followed by reintroduction of lactobacilli vaginally." | ( Eriksson, K; Forsum, U; Larsson, PG; Nilsson, M, 2011) |
| "In all, 63 consecutive women with bacterial vaginosis diagnosed by Amsel criteria were offered a much more aggressive treatment of BV than used in normal clinical practice with repeated antibiotic treatment with clindamycin and metronidazole together with vaginal gelatine capsules containing different strains of lactobacilli both newly characterised and a commercial one (109 freeze-dried bacteria per capsule)." | ( Andersen, KK; Brandsborg, E; Forsum, U; Hammarström, L; Larsson, PG; Marcotte, H; Nasic, S; Pendharkar, S, 2011) |
| "The "test all patients for bacterial vaginosis; treat if positive" strategy was also inexpensive, with a mean cost of $623 and 4." | ( Havrilesky, LJ; McElligott, KA; Myers, ER, 2011) |
| "Our objective was to evaluate whether bacterial vaginosis (BV) affected the pharmacokinetics of vaginally administered misoprostol during early pregnancy." | ( Fiala, C; Gemzell-Danielsson, K; Sandström, A; Schweer, H; Sioutas, A; Watzer, B, 2012) |
| "The multifactorial etiology of bacterial vaginosis (BV) impedes development of effective treatment and prevention strategies." | ( Cherpes, TL; Cosentino, LA; Kant, JA; Landsittel, D; Reighard, SD; Stoner, KA; Vicetti Miguel, RD, 2012) |
| "We investigated 199 pregnant women with bacterial vaginosis (BV) who received clindamycin vaginal cream (CVC) for three days and compared with 205 women treated with placebo." | ( Bassett, P; Lamont, RF; Taylor-Robinson, D, 2012) |
| "Untreated bacterial vaginosis is related with many complications for non-pregnant women in reproductive age, most common from them are vaginal discharge and postoperative infections." | ( Georgiev, S; Masseva, A; Nikolov, A; Shopova, E, 2012) |
| "Current treatment options for bacterial vaginosis (BV) have been shown to be inadequate at preventing recurrence and do not provide protection against associated infections, such as that with HIV." | ( Cavera, VL; Chikindas, ML; Singh, Y; Sinko, PJ; Sundara Rajan, S; Zhang, X, 2014) |
| "The following keywords were used: bacterial vaginosis and treatment or management or therapy or prophylaxis or prevention." | ( Donders, GG; Rezeberga, D; Zodzika, J, 2014) |
| "Women with bacterial vaginosis were treated with intravaginal metronidazole gel nightly for 5 nights." | ( Liao, Q; Na, RS; Nu, XX; Shang, CG; Wang, B; Wang, K; Xiao, BB, 2014) |
| "Sucrose gel was used to treat bacterial vaginosis in a phase III clinical trial." | ( Chen, Z; Cheng, H; Deng, QW; Hu, KT; Pan, WG; Wang, HY; Yang, WZ; Yu, ZJ; Zeng, ZM; Zheng, JX, 2015) |
| "During pregnancy, treating bacterial vaginosis and trichomoniasis with metronidazole is effective and offers no teratogen risk." | ( Berard, A; Ferreira, E; Santos, F; Sheehy, O, 2015) |
| "Current treatment for symptomatic bacterial vaginosis includes antibiotics, such as metronidazole, which are 70-80 % effective at one month after treatment and result in high recurrence rates and secondary candida infections." | ( Trouton, KM; Zeron Mullins, M, 2015) |
| "Then, patients were assessed for bacterial vaginosis on 90 ± 3 day after treatment." | ( Abbasalizadeh, S; Dehghan, P; Farhan, F; Farshbaf-Khalili, A; Hakimi, S; Javadzadeh, Y; Khalvati, B, 2018) |
| "However, bacterial vaginosis can alter treatment efficacy in HIV-infected women, and single-dose metronidazole treatment might not always clear infection." | ( Augostini, P; Beauchamps, L; Bradic, M; Carlton, JM; Kissinger, P; Lillis, RA; Martin, DH; Mena, LA; Muzny, CA; Myers, L; Schmidt, N; Schwebke, JR; Secor, WE; Taylor, SN, 2018) |
| "Treating bacterial vaginosis during pregnancy can reduce poor outcomes, such as preterm birth." | ( Ancel, PY; Bissinger, MC; Brabant, G; Canis, F; Chantrel, J; Deghilage, S; Delaeter, C; Desseauve, D; Dessein, R; Devos, P; Dugimont, JC; Faure, K; Fruchart, A; Gautier, S; Goffinet, F; Grandbastien, B; Guinard, E; Hacot, C; Jousse, M; Joyez, E; Kipnis, E; Nolf, C; Personne, A; Plennevaux, JL; Subtil, D; Tilloy, E, 2018) |
| "Following all forms of therapy for bacterial vaginosis (BV), recurrence rates are extremely high." | ( Aguin, T; Akins, RA; Boikov, D; Gill, G; Kaur, N; Sobel, JD; Woznicki, NA, 2019) |
| "The percent of bacterial vaginosis treatment was in 33(82." | ( Abbaspoor, Z; Afzali, E; Farajzadeh, A; Haghighi-Zadeh, MH; Siahposh, A, 2020) |
| "Twenty four adult women with confirmed bacterial vaginosis received the investigational product for self-administration on days 0, 2, 4, and 6 and were assessed on day 7." | ( Cardell, M; Gunnarsson, OS; Latham-Cork, HC; Säfholm, A; Strevens, H; Thornton, JG; Walker, KF, 2021) |
| "Recurrence of bacterial vaginosis (RBV) is a major challenge to effective therapy." | ( Akins, R; Sobel, JD; Surapaneni, S, 2021) |
| "The standard treatment for bacterial vaginosis (BV) with oral metronidazole is often ineffective, and recurrence rates are high among African women." | ( Abdool Karim, Q; Abdool Karim, SS; Balle, C; de Oliveira, T; Garrett, N; Giandhari, J; Jaspan, HB; Liebenberg, LJP; Mindel, A; Mngomezulu, K; Mtshali, A; Mzobe, G; Ngcapu, S; Onywera, H; Osman, F; Passmore, JS; Ravel, J; Rompalo, A; San, JE, 2021) |
| "Conventional antibiotic therapy for bacterial vaginosis has led to the accelerated process of bacterial drug resistance." | ( Chu, W; Jiang, Y; Lessing, DJ; Li, Y, 2022) |